Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group.
Goss PE, Winer EP, Tannock IF, Schwartz on behalf of the North American Vorozole Study Grou L. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. Journal Of Clinical Oncology 1999, 17: 52-63. PMID: 10458218, DOI: 10.1200/jco.1999.17.1.52.Peer-Reviewed Original ResearchConceptsPostmenopausal advanced breast cancer patientsAdvanced breast cancer patientsPhase III trialsBreast cancer patientsMegestrol acetateIII trialsCancer patientsTreatment groupsRandomized phase III trialUpper respiratory tract infectionSecond-line therapyAdvanced breast cancerDiscontinuation of treatmentRespiratory tract infectionsAromatase inhibitor vorozoleQuality of lifeMore dyspneaPostmenopausal womenAdverse eventsHot flushesMedian durationObjective responsePartial responseTamoxifen treatmentTract infections